Serum Sirtuin1 level decreases in Parkinson's disease and vascular parkinsonism: A prospective observational study
- PMID: 36709622
- DOI: 10.1016/j.clineuro.2023.107595
Serum Sirtuin1 level decreases in Parkinson's disease and vascular parkinsonism: A prospective observational study
Erratum in
-
Corrigendum to "Serum Sirtuin1 level decreases in Parkinson's disease and vascular parkinsonism: A prospective observational study" [Clin. Neurol. Neurosurg. 225 (2023) 107595-107599]'.Clin Neurol Neurosurg. 2023 Nov;234:107987. doi: 10.1016/j.clineuro.2023.107987. Epub 2023 Oct 14. Clin Neurol Neurosurg. 2023. PMID: 37839146 No abstract available.
Abstract
Objective: The present study aimed to investigate levels and clinical significance of serum SIRT1 in Parkinson's disease (PD) and Vascular parkinsonism (VP).
Methods: This prospective observational research enrolled a total of 165 VP and 159 PD patients who were admitted during March 2018 to December 2021. Blood samples and medical characteristics were also obtained from 160 healthy volunteers. The serum Sirtuin1 (SIRT1) and cytokines levels of all subjects were measured by enzyme-linked immunosorbent assay (ELISA) method. Demographic and clinical data were also collected. Statistical analysis was conducted using SPSS software with P < 0.05 as statistically different.
Results: The mean age, the UPDRSIII score of VP patients was significantly higher compared with the PD patients (p<0.05), while the MMSE score of VP patients was significantly lower than the PD patients (p<0.001). The serum SIRT1 levels of the VP patients were remarkably lower than the PD patients or the healthy persons (p<0.05). Pearson's analysis showed that SIRT1 levels were negatively correlated with levels of IL-6, TNF- α and hcy. The UPDRSIII of SIRT1 low levels group was remarkably higher than the SIRT1 high levels group (p=0.048), while the MMSE score was lower than the SIRT1 high levels group (p<0.001). In addition, ROC curves showed that SIRT1 could be a potential diagnostic biomarker of VP. SIRT1 was a risk factor for VP.
Conclusion: Our present study indicated that SIRT1 associated with disease severity and could discriminate PD from VP.
Keywords: Diagnostic biomarker; Parkinson's disease; SIRT1; UPDRS; Vascular parkinsonism.
Copyright © 2023. Published by Elsevier B.V.
Similar articles
-
Reduced serum SIRT1 levels in patients with Parkinson's disease: a cross-sectional study in China.Neurol Sci. 2021 May;42(5):1835-1841. doi: 10.1007/s10072-020-04711-z. Epub 2020 Sep 9. Neurol Sci. 2021. PMID: 32909152
-
The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular parkinsonism.PLoS One. 2011 Apr 27;6(4):e19333. doi: 10.1371/journal.pone.0019333. PLoS One. 2011. PMID: 21556377 Free PMC article.
-
Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1.J Nucl Med. 2001 Mar;42(3):408-13. J Nucl Med. 2001. PMID: 11337515
-
Vascular parkinsonism--an important cause of parkinsonism in older people.Age Ageing. 2005 Mar;34(2):114-9. doi: 10.1093/ageing/afi025. Age Ageing. 2005. PMID: 15713855 Review.
-
Vascular parkinsonism: what makes it different?Postgrad Med J. 2011 Dec;87(1034):829-36. doi: 10.1136/postgradmedj-2011-130051. Postgrad Med J. 2011. PMID: 22121251 Review.
Cited by
-
Vascular Impairment, Muscle Atrophy, and Cognitive Decline: Critical Age-Related Conditions.Biomedicines. 2024 Sep 13;12(9):2096. doi: 10.3390/biomedicines12092096. Biomedicines. 2024. PMID: 39335609 Free PMC article. Review.
-
The critical role of Sirt1 in ischemic stroke.Front Pharmacol. 2025 Mar 14;16:1425560. doi: 10.3389/fphar.2025.1425560. eCollection 2025. Front Pharmacol. 2025. PMID: 40160465 Free PMC article. Review.
-
Molecular targets and mechanisms of Sijunzi decoction in the treatment of Parkinson's disease: evidence from network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation.Front Pharmacol. 2024 Nov 26;15:1487474. doi: 10.3389/fphar.2024.1487474. eCollection 2024. Front Pharmacol. 2024. PMID: 39660000 Free PMC article.
-
Differences in Blood and Cerebrospinal Fluid Between Parkinson's Disease and Related Diseases.Cell Mol Neurobiol. 2024 Dec 27;45(1):9. doi: 10.1007/s10571-024-01523-z. Cell Mol Neurobiol. 2024. PMID: 39729132 Free PMC article. Review.
-
Atractylenolide-I Attenuates MPTP/MPP+‑Mediated Oxidative Stress in Parkinson's Disease Through SIRT1/PGC‑1α/Nrf2 Axis.Neurochem Res. 2024 Nov 18;50(1):18. doi: 10.1007/s11064-024-04258-x. Neurochem Res. 2024. PMID: 39556135
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical